mercoledì 29 giugno 2016

Cannabis Entrepreneurs Worried as Big Businesses Move Into Industry

Steve DeAngelo, a veteran marijuana activist turned entrepreneur, warns that as marijuana prohibition ends and corporations start entering the industry, the pioneers could lose their place to disruptive technologies and business models.

Staff writer, Inc.

Marijuana legalization means that bigger corporate interests and institutional capital will enter the industry and start competing with the businesses and entrepreneurs who have been at it for decades.
But what does this mean for the industry's activists and pioneers who protested federal law, got arrested, and created the very industry that is attracting attention as one of the fastest-growing sectors in the U.S. economy? Entrepreneurs will be displaced, says Steve DeAngelo, founder of Harborside, the largest dispensary in the U.S., during his keynote address at the National Cannabis Industry Association business summit and expo in Oakland on Wednesday.
DeAngelo explains that there are only ten states in the U.S.that haven't reformed their cannabis laws in some way, there are eight ballot measures across different states to pass more reform this November, and the DEA could recognize that cannabis has medical benefits and might reschedule it this summer. All of this change will open the industry up to new entrants, bigger, more mainstream companies, and institutional investment. While legalization will be overwhelmingly positive, it won't be without negative effects on the current industry.
"This is going to the painful, it will hurt a lot of people who have been in the industry for decades," says DeAngelo. "It's going to hurt the very people who have helped bring the industry to today."
DeAngelo explained that industry newcomers have the ability to raise more money than legacy players because they have more connections to active capital markets outside of cannabis, he says. The new entrants will introduce disruptive business models that will force legacy businesses to change the way they have been doing things for decades.
"Legacy cannabis companies will need to learn how to adapt to a much more intense competitive environment and changing cultural landscape," says DeAngelo. "The folks coming in are not from the cannabis underground, they come with different values. There will be a process of adaptation for the legacy entrepreneurs."
A lot of the folks coming into the legal cannabis market are from other industries and have established political power and financial resources, says DeAngelo.
"Some of these players have been able to influence legislation to game the system to their benefit," says DeAngelo. "In Nevada, there is a provision that gives the distribution of cannabis exclusively to alcohol distribution companies. Guess who put that one in there?"
As the DEA and FDA look to possibly reschedule marijuana under the Controlled Substances Act, DeAngelo says if the federal government decides marijuana has medical benefits, it will help pharmaceutical companies enter the industry.
"It's evident that rescheduling will be a platform for Big Pharma to come in and take significant marketshare," says DeAngelo.
But as different formulations of cannabis hit the market, more people will try cannabis products.
"More sophisticated products like vape pens, transdermal patches, pills, topical creams, beverages and edibles will provide new adopters, newcomers to cannabis with more socially acceptable ways of using cannabis," says DeAngelo.
Once federal law is reformed and national brands are created, institutional investors will come into he space and start acquiring the strongest brands.
"The institutional investors are almost here, I can hear them in the hall way," says DeAngelo. "When they come, there will be a rich wave of exits, of acquisitions of companies who have played their cards right and been smart. I think those first acquisitions will be science companies, medical companies, companies that do genetics, others that explore new formulations. We will then see cannabis beverage companies that will be acquired by huge mainstream beverage corporations, companies that already make beverages at large scale."
As the cannabis industry changes, as more companies come into the market from outside of the industry, more customers will come to use cannabis.
"I don't think this is a bad thing," says DeAneglo. "All of this is a good thing. There is this monumental collision that is about to happen between the corporate world and cannabis. If we are ever going to achieve our goal, if this plant is ever going to get in the hands of people all over the world, this will be necessary."
Lastly, DeAngelo spoke directly to the legacy entrepreneurs and the newcomers.
The legacy entrepreneurs, DeAngelo says, are going to be called upon to make one more sacrifice--to let go of the cannabis plant and let it go completely mainstream, which will mean some pioneers will lose their place and new entrants will replace them.
"Let's make this sacrifice gracefully, we need to release this plant and allow her to go out, get wings, claim her destiny, to go out and help every single person she can help and we are not going to do it ourselves," says DeAngelo. "We have to welcome these newcomers, we need to let them help the industry."

venerdì 17 giugno 2016

Medical marijuana company gets the OK to build facility in Fall River

Marijuana will be grown and processed into medicine in a laboratory planned for the city’s biotech office park.

By Kevin P. O'Connor 

Herald News Staff Reporter  

Posted Jun. 10, 2016 at 3:47 PM

Updated Jun 10, 2016 at 3:56 PM 

FALL RIVER — Marijuana will be grown and processed into medicine in a laboratory planned for the city’s biotech office park.

Cannatech Medicinals Inc., a company based in Fall River, got Phase 3 approval from the state Department of Public Health to build a 30,000-square-foot facility at the Southcoast Life Science and Technology Park.
“We are hoping to break ground in the next 30 days,” said Dr. Henry Crowley, company president. “At this point, it is unlikely that anything will halt us.”
Cannatech got approval in December to buy 12 acres of land from the city’s Redevelopment Authority at a price of $1.02 million. That, plus a letter of support from Mayor Jasiel Correia II and a letter of non-opposition from Police Chief Daniel Racine, allowed the company to apply for a medical marijuana producer’s license.
That was received last week, so the company can begin plans for building, Crowley said.
“We are pulling permits now,” he added.
The facility in the office park will be dedicated to growing marijuana plants, testing the properties of different strains and producing oils, edibles and vaporizing agents for consuming the drug.
“Our goal to the consumers and to the community is to produce a high-quality medicine in a facility that will achieve the same standards as any high-tech pharmaceutical facility in the country,” Crowley said.
“Our ultimate goal is to provide a physician-directed method of treating diseases effectively with medical cannabis.”
The facility will be closed to the public. Cannatech purchased a lot on Hartwell Street to house a dispensary, Crowley said.
Cannabis remains illegal under federal law, but Massachusetts is one of several states that allow the production and distribution of the drug for medical purposes.
State voters will be asked in November of the recreational use of marijuana should be made legal. That vote won’t affect the work of Cannatech, Crowley said.
“We are a medical company and we are in it for medical purposes,” he said. “Our emphasis is on medical marijuana.
“We will have a strong and aggressive research and development department for that purpose.”
More than a decade of experiments in Israel and the Netherlands have shown different strains of cannabis effective at curbing epilepsy, shrinking cancerous tumors, slowing the development of glaucoma and dealing with chronic pain or side affects from HIV.
Crowley, who is an anesthesiologist and trained in pain management, said he has been following the development of cannabis medicines for more than five years. Derek Ross, who will be in charge of botany, is nationally recognized for his expertise in hybridizing strains of cannabis to target specific ailments, Crowley said.
“There is a lot of potential for this as a medicine for treating chronic disease,” he said.
Crowley and Steven Pimental, a partner in Cannatech, are both part of Same Day SurgiClinic, 272 Stanley St. It has been their intention from the start to locate in Fall River, Crowley said.

“The city of Fall River has been very helpful and very accommodating,” Crowley said. “The mayor and his legal team and Ken Fiola and his office have been fantastic.

“We want to be good neighbors. We will be giving back to the community.”
The plan is to have a facility built in six to eight months. There should be about 30 people employed there initially. The company should have products ready for sale in 16 to 18 months after the start of construction, Crowley said. The hope is to expand the plant in the next decade and grow to 100 employees, Crowley said.
There is a push, nationally, to remove cannabis from the list of federally prohibited drugs to allow medical research. Right now, cannabis, in all its forms, is a federal Schedule 1 drug, up there with heroin and cocaine.
“Until cannabis is de-scheduled, there probably won’t be a lot of research and development with it,” Crowley said. “When it is, we want to be at the forefront of it.”

Medical marijuana company gets the OK to build facility in Fall River

mercoledì 15 giugno 2016

mCig, Inc. Announces Scope of Project Expansion and Shareholder Gathering at Green Leaf Facility on July 15th at 2:00 PM
HENDERSON, NV--(Marketwired - Jun 10, 2016) 

Scalable Solutions, Inc., a subsidiary of mCig, Inc. (OTCQB: MCIG), the emerging leader in Marijuana Cultivation construction, will host a shareholder and client gathering at the 30,000 square foot Green Leaf facility to tour the warehouse facility. During this gathering, MCIG's Grow Division will discuss the project, including the recent expansions of a 2,000 square ft. production and extraction kitchen.Shareholders should note that by the numbers, the current Green Leaf project is priced at $1,695,000 with over $200,000 in consulting fees built into the construction project. Phase 1 is now valued at $805,085 with slightly more of the pro-rata profit and consulting fees upfront. As of today, Scalable Solutions finished designing a new addition to the scope of work, a production facility which will add approximately $500,000 including fees of project improvements once finalized, with potential for more upgrades. To date, demolition and site layout were finished last month and all progress on projects can be viewed at a renewed effort to keep shareholders informed and expand its growing portfolio of products and services, MCIG will use Green Leaf's media arm as an added built-in bonus. This MCIG Green Leaf co-venture allows the exchange of consulting services and media outreach at no cost for either party, yet allows for savings by pooling certain skill sets and by no means detracts from construction profits in any way, shape or form.About Scalable Solutions, Inc.

Headquartered in Henderson, Nevada, Scalable Solutions, Inc., is dedicated to servicing the Cannabis industry as a leading large scale Cannabis cultivation construction company and consultant. The company provides full planning, design, construction, equipment, and consulting services for large scale grows, modular Growpod technology for warehouse conversions, and a line of home grow units to fully capture all aspects of Cannabis growers' needs.About mCig, Inc.Headquartered in Henderson, Nevada, mCig Inc. (OTCQB: MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. MCIG has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Scalable Solutions division currently operating in the rapidly expanding Nevada market. The company looks forward to growing its core competencies to service the Ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. For more information visit Player's NetworkPlayer's Network is a diversified company with holdings in both Media and Medical Marijuana. The Company uses its proprietary Enterprise Web Platform to develop Branded Digital Lifestyle Television Networks for itself and its partners in a wide range of lifestyle categories. Player's Network's current original channels, "Player's Network," "Vegas on Demand," "Real Vegas TV," focus on the Las Vegas and Gaming Lifestyles. These channels are distributed over PNTV's owned and operated VOD Channels over its Broadband Network and Mobile Platforms. The Medical Marijuana assets are primarily through the Company's 80% ownership in Greenleaf Farms Holdings, and PNTV's newest channel, "," which focuses on the rapidly expanding cannabis community. For more information please visit Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.

mCig, Inc. Announces Scope of Project Expansion and Shareholder Gathering at Green Leaf Facility on July 15th at 2:00 PM

sabato 11 giugno 2016

DEA Set to Rule on Crucial Rescheduling of Marijuana

If the DEA reschedules marijuana, the industry could be welcomed into the mainstream economy.

The U.S. Drug Enforcement Agency is about to make a decision that could have wide-ranging implications on the state-sanctioned marijuana industry: to reschedule or not to reschedule marijuana's position as an illegal substance.
Since 1970, marijuana has been on the list of Schedule I drugs, which defines chemicals under the Controlled Substances Act as a drug with high potential for abuse and no medical benefits. Marijuana, heroin, and LSD are Schedule I drugs, while cocaine, methamphetamine, and oxycodone are Schedule II. Drugs are rescheduled often, but marijuana has been deemed a Schedule I substance for 46 years, which makes it illegal to grow, possess, use, or distribute under federal law.
The DEA has already received the Food and Drug Administration's recommendation on the rescheduling, which is a key part of the rescheduling process stipulated by the Controlled Substance Act, says Russell Baer, a special agent at the DEA's office of public affairs. Baer won't reveal what the recommendation was. The DEA will now conduct its own eight-factor analysis to study the drug's potential for abuse, the current state of medical and scientific knowledge, the history and pattern of abuse, and other considerations. Once that is complete, the DEA's administrator, Chuck Rosenberg, makes the final call.
Baer says the decision will be in line with the current scientific and medical findings surrounding marijuana's status as a beneficial drug.
"We are bound by the FDA's scheduling recommendations," says Baer.
If the DEA recommends rescheduling marijuana to II, III, IV, or V, or removing it from the list of controlled substances, any change in designation will have big implications for the legal industry across 23 states and Washington, D.C., says Aeron Sullivan, the co-founder of Tradiv, an online wholesale marketplace for legal marijuana businesses to buy and sell marijuana. If pot is rescheduled, it could also open up the industry to import-export and help increase the potential for a nationwide, regulated market. In short, it could welcome marijuana into the mainstream economy.
But if the DEA decides marijuana is still a Schedule I drug, Baer says the agency will not be dropping down into Colorado, Washington, and Oregon from black helicopters and arresting everyone.
"Even if it remains a Schedule I substance, the DEA will continue to allocate its resources and time to the biggest and most violent drug traffickers," he says, explaining most of the agency's resources are being used to deal with the current opioid epidemic, which kills more people each year than auto accidents.
While the states are technically breaking federal law, the DEA is not going to waste its resources on regulated marijuana industries that have been approved by local voters, Baer says.
Baer wouldn't give a specific date for the decision, but he said the process is nearly complete and the agency is waiting to hear Rosenberg's decision whether marijuana is considered a medicine or if it's still a dangerous substance. 
While the DEA continues to deliberate the rescheduling of cannabis, the agency will continue to support increased medical and scientific studies on weed, says Baer.
According to the DEA, the total number of Schedule I researchers registered to study marijuana and its extracts, concentrates, and active compounds has increased from 161 in April 2014 to 344 in March 2016, an increase of more than 113 percent.
Baer said the DEA is also working to build an on-line application system for researchers to apply for a Schedule I researcher registration to make the application and review process easier and to promote more scientific and medical research on the plant.

giovedì 9 giugno 2016

Forget Colorado Weed, Marijuana Companies Are Going Global

Legal marijuana is already a global industry and the U.S. is behind the curve


Staff writer, Inc.@WillYakowicz

When you think of the legal marijuana industry, you think of Colorado and California. But marijuana is not uniquely American, nor is the legalization movement.
Medical and recreational marijuana is a multi-billion dollar global industry, with various  programs either ready to be implemented or already up and running in countries like Canada, Australia, Germany, Italy, and the Czech Republic. Despite global drug policy, marijuana is grown, distributed and used all over the world. While Colorado and California are looked at as models of the modern marijuana economy, the U.S. lags behind other countries like Canada, which already has a fully-functional nationwide medical program and will launch its nationwide recreational program in the next year.
Brendan Kennedy, the cofounder of Privateer Holdings, which owns various marijuana companies like Marley Natural and Canadian pharmaceutical-grade cannabis producer Tilray, says his companies are expanding abroad while the U.S. Drug Enforcement Agency and the Food and Drug Administration debate whether or not to treat the plant as a medicine or keep it in the same category as heroin.
"People think cannabis legalization is a U.S. phenomenon or even a western U.S. paradigm shift, but this is taking place around the world," says Kennedy. "It's a misconception to think this is a Californian thing, or a Colorado thing. It's much larger than that. We look at marijuana from a global perspective."
Kennedy has been to Spain, Portugal, Germany, the Czech Republic, and Italy in the last six months to explore marijuana business opportunities. Currently in the U.K., he will go back to Privateer's headquarters in Seattle, then visit Tilray's 60,000-square foot facilities in British Columbia, Canada, then to Australia, where Tilray has an import license to send marijuana for a clinical trial with a chemotherapy-induced nausea and vomiting study with the University of Sydney, the government of New South Wales and the country's largest cancer hospital.
"These places are already far ahead of the U.S. in terms of implementing and regulating this product as a medicine," says Kennedy. "We spend time in places like these in hopes to build cultivation facilities or import our medical cannabis and medical cannabis products while the DEA and FDA are debating the potential rescheduling."
Marijuana is being produced around the world, from Israel to Australia. Above, the growing facility of the Tikun Olam in Safed, Israel, with Israel's Health Ministry, distributes cannabis for medicinal purposes to over 1800 people. (Photo by Uriel Sinai/Getty Images) CREDIT: Getty Images
As the U.S.-based industry awaits that ruling, companies are looking in other countries to hedge their bets on a global, import-export industry. Kennedy says that as marijuana reform spreads across the world, a global economy is forming and marijuana production will start to blossom where other commodities are currently grown, such as coffee, fruit, cotton, tobacco and medicinal opium poppies. 
"For us, it's more about environmental sustainability and ultimately, it's a crop that is the basis for this product and it should be grown in an environment where sunshine is plentiful," says Kennedy. 
Tilray is not the only company that has an import-export license to send marijuana to other countries. U.K.-based GW Pharmaceuticals, which is extracting CBD from the cannabis plant to make anti-seizure medication, already has an import-export licenses for marijuana. O.penVape, which is a vaporizer company based in Denver, recently announced a licensing agreement with a Jamaica-based company to grow pot for its vaporizers. 
As marijuana slowly emerges from prohibition, it will be easier for companies to legally grow in other countries where there are more ideal climates and water tables that will help lower prices and the indoor grow methods created to escape the DEA's helicopters will become history, Kennedy says. 
"If I could short the indoor grow market in Denver, I would," says  Kennedy. "You have to look at other models of tightly controlled agricultural products used for medical purposes, like poppies, which are grown in Australia, Spain and other climates that are beneficial for low-cost production. The bulk of marijuana produced around the world will be grown outside in greenhouses or fields."
As marijuana grows head to cheaper pastures outside in states and counties with ideal climates, like California, Texas, Florida, Mexico, Australia, Israel, and South East Asia, each region will have its own properties.  
Just like the wine industry, marijuana from specific regions will be defined by its terroir, Kennedy says. Marijuana's terroir could include pot grown in Humboldt, the Emerald Triangle, pot grown near the Sea of Galilee, weed from the Golden Triangle of South East Asia or cannabis grown under the shade of olive trees in Spain, Kennedy suggests.
"I don't think Denver warehouse terroir will be that appealing or competitive," Kennedy says. 
Aeron Sullivan, the co-founder of Tradiv, an online wholesale marketplace for legal pot businesses to buy and sell marijuana, says there is no doubt pot production will be outsourced to other regions of the world and the southern states in the U.S. 
"Once you can import and export marijuana easily, you will see facilities in places where you can produce as efficiently as possible," says Sullivan, who was recently named on Inc.'s 30 Under 30 list. "Right now in Humboldt, cost per gram is at $1. Why not set up greenhouses in Cambodia with its renewable water tables and grow for ten cents a gram? You can fly over a ton of marijuana for a fairly inexpensive amount."
Sullivan says the U.S. is not the only country moving fast to favorable drug reformation. Pretty soon, he says, the global industry will be up and running and major corporations will have energy efficient grows outside, producing metric ton after metric ton of high-grade marijuana at a low cost production.
"It's a commodity, it's going to grow where ever the commodity grows," says Sullivan. "Oranges grow in Florida, avocados grow in Mexico. Sativa originated in India and commodities grow where they like to grow."

Forget Colorado Weed, Marijuana Companies Are Going Global

domenica 5 giugno 2016

The Keurig Of Marijuana? CannaKorp Banks On Pods Filled With Pot


When Michael Bourque, an engineer, was prescribed medical marijuana, he found the whole endeavor of taking it a bit daunting. How much should he buy and how strong was it? How should he prepare it?
Like many marijuana patients, Bourque wanted consistent dosage, standardized packaging, easy administration and no mess. As an engineer he decided he could invent his way out of the problem.
Bourque teamed up with Dave Manly a former vice president at Keurig Green Mountain GMCR +% Inc., maker of the pod coffee machine and James Winokur, a technology executive and now the company’s CEO. The trio dreamed up a machine similar to the Keurig coffee maker, but for marijuana vaporization.  Users would insert a single-use pod of cannabis into the device, which would heat it and releases the vapor to be inhaled.
CannaCloud by CannaKorps (Photo courtesy of CannaKorps)
CannaCloud by CannaKorps (Photo courtesy of CannaKorps)
Soon two other retired Keurig executives joined the CannaKorp Inc. team. “They said they missed the entrepreneurial spirit they had at work,” said James. The machine they created, CannaCloud, will make its sales debut in Boulder Colorado at the end of 2016.
Early feedback has been enthusiastic. “We showed our invention off at the MarijuanaBusiness Daily cannabis trade show in Las Vegas last year and the booth got really crowded,” said Winokur. Greg James, who was there to talk to the founders about joining the company, even jumped in and started giving product demonstrations. Now he is Vice President of Sales and Marketing.
The Stoneham Massachusetts company currently employees eight people.
While the $149.95 CannaCloud vaporizers will be sold at dispensaries to patients, the founders have created another device that loads pre-ground cannabis into the pods, the “CannaMatic.” They plan to sell this machine to cannabis growers and processors in different states. Vetted and trained, these partners will fill and sell cannabis pods locally, said James.

venerdì 3 giugno 2016

Festa Parmigiana Antiproibizionista, sabato, 04. giugno 2016, Parma

In occasione del 14° compleanno del Canapaio Ducale Parma, la bottega più longeva ed antiproibizionista di Parma, ecco a voi l'annuale Festa Parmigiana Antiproibizionista!
- Apertura festa alle 16.20
Dalle 17,30 le conferenze
- "CANNABINOIDI, CANNABIS E CANAPA: cosa, come e quanto". Le proprietà terapeutiche dei cannabinoidi;
- "GEOPOLITICA DELLA CANNABIS: come, dove e perchè le nazioni regolamentano la marijuana";
Dalle 20,30 i dj set
- Robert PASSERA (lounge, nujazz);
- Steve GIANT (roots reggae) Rastasnob Italian Reggae Magazine;
- PAPALUKA (roots reggae) Luca Papaluka Cazzaro;
- Vito WAR (roots reggae) Vitowar;
- FUMISKIO Sound (funky, hip hop).
Stand informativi, commerciali ed espositivi, birra ed alimenti in canapa e molte sorprese durante tutta la giornata.
Ingresso, come sempre, GRATUITO ma con tessera ARCI anche da fare sul posto a prezzo politico.
Aiutaci a divulgare l'evento condividendolo ed invitando i tuoi amici.
Durante la festa sarà possibile firmare la proposta di legge sulla Cannabis Legale (
Main sponsor: CULTILITE (;
Media partner: Dolce Vita Magazine
Partner politico: Associazione Luca Coscioni